EE03606B1 - Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) - Google Patents
Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)Info
- Publication number
- EE03606B1 EE03606B1 EE9800015A EE9800015A EE03606B1 EE 03606 B1 EE03606 B1 EE 03606B1 EE 9800015 A EE9800015 A EE 9800015A EE 9800015 A EE9800015 A EE 9800015A EE 03606 B1 EE03606 B1 EE 03606B1
- Authority
- EE
- Estonia
- Prior art keywords
- calcium
- atorvastatin
- phenylamino
- methylethyl
- fluorophenyl
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- 229910052791 calcium Inorganic materials 0.000 title 2
- 239000011575 calcium Substances 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US145295P | 1995-07-17 | 1995-07-17 | |
PCT/US1996/011368 WO1997003959A1 (en) | 1995-07-17 | 1996-07-08 | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9800015A EE9800015A (et) | 1998-08-17 |
EE03606B1 true EE03606B1 (et) | 2002-02-15 |
Family
ID=21696090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9800015A EE03606B1 (et) | 1995-07-17 | 1996-07-08 | Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) |
Country Status (38)
Country | Link |
---|---|
US (1) | US5969156A (et) |
EP (2) | EP1148049B1 (et) |
JP (4) | JP3296564B2 (et) |
KR (2) | KR100431038B1 (et) |
CN (1) | CN1087288C (et) |
AR (2) | AR003458A1 (et) |
AT (3) | ATE284868T1 (et) |
AU (1) | AU725424B2 (et) |
BG (1) | BG63630B1 (et) |
BR (1) | BR9609872A (et) |
CA (1) | CA2220018C (et) |
CO (1) | CO4700443A1 (et) |
CY (1) | CY2358B1 (et) |
CZ (3) | CZ294108B6 (et) |
DE (2) | DE69616808T2 (et) |
DK (2) | DK1148049T3 (et) |
EA (1) | EA000474B1 (et) |
EE (1) | EE03606B1 (et) |
ES (2) | ES2167587T3 (et) |
GE (1) | GEP20002029B (et) |
HK (1) | HK1018052A1 (et) |
HR (1) | HRP960339B1 (et) |
HU (1) | HU223599B1 (et) |
IL (7) | IL128864A (et) |
MX (1) | MX9709099A (et) |
NO (1) | NO309898B1 (et) |
NZ (1) | NZ312907A (et) |
PE (1) | PE1898A1 (et) |
PL (1) | PL193479B1 (et) |
PT (2) | PT1148049E (et) |
RO (1) | RO120070B1 (et) |
SI (2) | SI0848705T1 (et) |
SK (1) | SK284202B6 (et) |
TW (1) | TW486467B (et) |
UA (1) | UA51661C2 (et) |
UY (2) | UY24285A1 (et) |
WO (1) | WO1997003959A1 (et) |
ZA (1) | ZA966044B (et) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
CZ294108B6 (cs) * | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
IN191236B (et) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
EP1535613B1 (en) * | 1999-11-17 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Process for preparing a polymorphic form of atorvastatin calcium |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
EP1237865B1 (en) | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
CA2391357C (en) * | 1999-12-17 | 2009-01-06 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US6258767B1 (en) * | 2000-04-26 | 2001-07-10 | Colgate-Palmolive Co. | Spherical compacted unit dose softener |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
CZ20023826A3 (cs) * | 2000-06-09 | 2003-04-16 | Lek Pharmaceuticals D. D. | Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující |
MXPA03003900A (es) * | 2000-11-03 | 2005-02-17 | Teva Pharma | Forma vii de hemicalcio de atorvastatina. |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
KR20030081353A (ko) * | 2000-12-18 | 2003-10-17 | 큐비스트 파마슈티컬즈 인코포레이티드 | 정제된 리포펩티드의 제조 방법 |
US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
DE60137364D1 (de) * | 2000-12-27 | 2009-02-26 | Teva Pharma | Kristalline formen von atorvastatin |
EP1724256A3 (en) | 2001-01-09 | 2007-03-21 | Warner-Lambert Company LLC | Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
US6476235B2 (en) | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
CZ20033478A3 (cs) * | 2001-06-29 | 2004-10-13 | Warner@Lambertácompanyállc | Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB |
ES2286270T3 (es) * | 2001-07-19 | 2007-12-01 | Pharmacia Corporation | Combinacion de un antagonista del receptor de aldosterona y un inhibidor de la hmg coa reductasa. |
BR0211488A (pt) | 2001-07-30 | 2004-08-17 | Reddys Lab Ltd Dr | Formas cristalinas vi e vii de atorvastina cálcica |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
MXPA04001451A (es) * | 2001-08-16 | 2005-02-17 | Teva Pharma | Procesos para preparar formas de sal de calcio de estatinas. |
US20060173064A1 (en) * | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
US6569887B2 (en) | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
HU227124B1 (en) * | 2001-09-14 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
CA2475864A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
EP1465901A4 (en) * | 2002-02-19 | 2006-02-01 | Teva Pharma | PROCESS FOR THE DESOLVATION OF ATORVASTATIN HEMI-CALCIUM SOLVATES AND OF ESSENTIALLY SOLVENT-FREE ATORVASTATIN HEMI-CALCIUM |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
HUP0201083A2 (hu) * | 2002-03-28 | 2004-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
PL375415A1 (en) * | 2002-08-06 | 2005-11-28 | Warner-Lambert Company Llc | Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
HRP20020885B1 (en) * | 2002-11-11 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A |
EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
CA2519458A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
CN1774421A (zh) * | 2003-04-14 | 2006-05-17 | 沃尼尔·朗伯有限责任公司 | 制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法 |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
WO2004103959A2 (en) * | 2003-05-16 | 2004-12-02 | Ambit Biosciences Corporation | Heterocyclic compounds and uses thereof |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20040242670A1 (en) * | 2003-06-02 | 2004-12-02 | Sonny Sebastian | Process for preparation of amorphous atorvastatin calcium |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
US20070276027A1 (en) * | 2003-09-17 | 2007-11-29 | Warner-Lambert Company Llc | Crystalline Forms of [R-(R* ,R*)]-2-(4-Fluorophenyl)-Beta, -Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
CA2547573A1 (en) * | 2003-12-05 | 2005-06-23 | Warner-Lambert Company Llc | N-alkyl pyrroles as hmg-coa reductase inhibitors |
CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
EP1761489A1 (en) * | 2004-03-17 | 2007-03-14 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
CN1942439B (zh) | 2004-03-17 | 2011-12-21 | 兰贝克赛实验室有限公司 | 无定形形式的阿托伐他汀钙的制备方法 |
EP1740549A2 (en) * | 2004-04-16 | 2007-01-10 | Warner-Lambert Company LLC | Novel imidazoles |
US20070225353A1 (en) * | 2004-04-16 | 2007-09-27 | Pfizer, Inc. | Process for Forming Amorphous Atorvastatin |
WO2005105738A2 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of atorvastatin |
HUE029911T2 (en) * | 2004-07-16 | 2017-04-28 | Lek Pharmaceuticals | Products of atorvastatin calcium oxidative degradation |
JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | [R−(R*,R*)]−2−(4−フルオロフェニル)−β、δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)の新規形態 |
CA2575243A1 (en) * | 2004-07-22 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
CA2578722C (en) | 2004-08-27 | 2010-02-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
KR100881103B1 (ko) * | 2004-09-28 | 2009-02-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법 |
US20060106230A1 (en) | 2004-10-18 | 2006-05-18 | Michael Pinchasov | Processes for preparing amorphous atorvastatin hemi-calcium |
EP1807055A1 (en) * | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
WO2006048888A1 (en) * | 2004-11-01 | 2006-05-11 | Jubilant Organosys Limited | Novel process for the preparation of amorphous atorvastatin calcium salt |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
US20060100263A1 (en) * | 2004-11-05 | 2006-05-11 | Anthony Basile | Antipyretic compositions and methods |
US20090208539A1 (en) * | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
EP1819681B1 (en) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
WO2006059210A2 (en) * | 2004-12-03 | 2006-06-08 | Warner-Lambert Company Llc | Fused bicyclic pyrrols as hmg-coa reductase inhibitors |
EP1671947A1 (en) * | 2004-12-20 | 2006-06-21 | Ratiopharm GmbH | Process for preparing pyrrole derivatives and intermediates |
RU2409563C2 (ru) * | 2005-04-08 | 2011-01-20 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина |
PT1919466E (pt) | 2005-07-11 | 2012-05-21 | Cortria Corp | Formulações para tratamento de anormalidades de lipoproteína compreendendo uma estatina e um derivado de metilnicotinamida |
BRPI0613943B1 (pt) * | 2005-07-27 | 2021-06-22 | Otsuka America Pharmaceutical, Inc | Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa |
US20070032665A1 (en) * | 2005-08-04 | 2007-02-08 | Srinivasulu Gudipati | Preparation of atorvastatin calcium form i |
EP1928823B1 (en) | 2005-08-15 | 2014-10-08 | Arrow International Limited | Process for preparing crystalline sodium salt of ATORVASTATIN |
CA2619040C (en) | 2005-08-15 | 2015-02-10 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
WO2007030302A2 (en) * | 2005-09-01 | 2007-03-15 | Prescient Medical, Inc. | Drugs coated on a device to treat vulnerable plaque |
CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
US8080672B2 (en) * | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
WO2007096903A2 (en) * | 2006-02-22 | 2007-08-30 | Matrix Laboratories Ltd | New crystalline form of atorvastatin hemi-calcium |
US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2787343C (en) | 2006-06-26 | 2016-08-02 | Amgen Inc. | Compositions comprising modified lcat and uses thereof |
KR20080031487A (ko) * | 2006-06-28 | 2008-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴의 결정형 |
WO2008042876A2 (en) | 2006-10-02 | 2008-04-10 | Codexis, Inc. | Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor |
US20080269348A1 (en) * | 2006-11-07 | 2008-10-30 | Phil Skolnick | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use |
US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
KR100878140B1 (ko) * | 2007-01-29 | 2009-01-12 | 한미약품 주식회사 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
PT103661B (pt) * | 2007-02-23 | 2010-09-07 | Hovione Farmaciencia S A | Processo de preparação de minociclina base cristalina |
CA2679317A1 (en) * | 2007-03-02 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel crystal forms of pyrrolylheptanoic acid derivatives |
US20080249141A1 (en) * | 2007-04-06 | 2008-10-09 | Palepu Nageswara R | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
JP2010523659A (ja) * | 2007-04-09 | 2010-07-15 | サイドース・エルエルシー | スタチン類と抗肥満症薬との組み合わせ |
US20090069374A1 (en) * | 2007-06-06 | 2009-03-12 | Phil Skolnick | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments |
US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
WO2009013633A2 (en) * | 2007-07-20 | 2009-01-29 | Actavis Group Ptc Ehf | Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
US8168416B2 (en) | 2007-07-26 | 2012-05-01 | Amgen Inc. | Modified lecithin-cholesterol acyltransferase enzymes |
MX2010003056A (es) | 2007-09-21 | 2010-04-07 | Epiphany Biosciences Inc | Polimorfos de valomaciclovir. |
KR100813666B1 (ko) * | 2007-10-23 | 2008-03-14 | (주)에이에스텍 | 콜레스테롤 합성 저해제로서 아토르바스타틴의 프로드럭 |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
WO2009140341A2 (en) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
EP2414529A2 (en) | 2009-04-01 | 2012-02-08 | Matrix Laboratories Ltd | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
EP2630121A1 (en) * | 2010-09-30 | 2013-08-28 | Wisconsin Alumni Research Foundation | (20r,25s)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin d3 in crystalline form |
HU230737B1 (hu) | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
MX2013015272A (es) | 2011-07-01 | 2014-04-14 | Dsm Sinochem Pharm Nl Bv | Cristales micronizados. |
RU2014124118A (ru) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | Фармацевтические препараты, включающие аторвастатин и глимепирид |
EP2788384B1 (en) | 2011-12-08 | 2017-08-09 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
MX2014012349A (es) * | 2012-04-30 | 2015-01-12 | Hoffmann La Roche | Nueva formulacion. |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
ES2822561T3 (es) | 2014-09-15 | 2021-05-04 | Univ Leland Stanford Junior | Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis |
EP4218812A1 (en) | 2015-02-27 | 2023-08-02 | The Board of Trustees of the Leland Stanford Junior University | Combination therapy for treatment of atherosclerosis |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
EP3501502A1 (en) | 2017-12-20 | 2019-06-26 | Midas Pharma GmbH | Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin |
CN108558726A (zh) * | 2018-03-14 | 2018-09-21 | 湖北广济药业股份有限公司 | 一种高纯度阿托伐他汀钙的制备方法 |
CN110776451B (zh) * | 2020-01-02 | 2020-05-22 | 湖南迪诺制药股份有限公司 | 一种i晶型阿托伐他汀钙的制备方法 |
KR20210001641U (ko) | 2020-01-08 | 2021-07-16 | 주식회사 다마가산업 | 최소구성의 초저가 콘크리트 타설 레벨표시구 |
EP4052695A1 (en) | 2021-03-05 | 2022-09-07 | Midas Pharma GmbH | Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456753A (en) | 1983-02-07 | 1984-06-26 | Pfizer Inc. | Process for the manufacture of highly crystalline sodium cefoperazone |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
DE4235133A1 (de) | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
JP3623531B2 (ja) | 1993-06-07 | 2005-02-23 | ビーエーエスエフ アクチェンゲゼルシャフト | 結晶質l−アスコルビン酸−2−燐酸エステルマグネシウム塩の製造法 |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
CZ294108B6 (cs) * | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
CA2391357C (en) | 1999-12-17 | 2009-01-06 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
EP1237865B1 (en) | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
CZ20033478A3 (cs) | 2001-06-29 | 2004-10-13 | Warner@Lambertácompanyállc | Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB |
-
1996
- 1996-07-08 CZ CZ1998121A patent/CZ294108B6/cs not_active IP Right Cessation
- 1996-07-08 DE DE69616808T patent/DE69616808T2/de not_active Revoked
- 1996-07-08 KR KR10-2002-7017608A patent/KR100431038B1/ko not_active IP Right Cessation
- 1996-07-08 AU AU64842/96A patent/AU725424B2/en not_active Expired
- 1996-07-08 ES ES96924368T patent/ES2167587T3/es not_active Expired - Lifetime
- 1996-07-08 EE EE9800015A patent/EE03606B1/et unknown
- 1996-07-08 EP EP01116338A patent/EP1148049B1/en not_active Revoked
- 1996-07-08 BR BR9609872A patent/BR9609872A/pt not_active IP Right Cessation
- 1996-07-08 DK DK01116338T patent/DK1148049T3/da active
- 1996-07-08 IL IL128864A patent/IL128864A/en not_active IP Right Cessation
- 1996-07-08 US US08/945,812 patent/US5969156A/en not_active Expired - Lifetime
- 1996-07-08 AT AT01116338T patent/ATE284868T1/de active
- 1996-07-08 CA CA002220018A patent/CA2220018C/en not_active Expired - Lifetime
- 1996-07-08 WO PCT/US1996/011368 patent/WO1997003959A1/en active Application Filing
- 1996-07-08 PT PT01116338T patent/PT1148049E/pt unknown
- 1996-07-08 ES ES01116338T patent/ES2233526T3/es not_active Expired - Lifetime
- 1996-07-08 IL IL128865A patent/IL128865A/en not_active IP Right Cessation
- 1996-07-08 SI SI9630355T patent/SI0848705T1/xx unknown
- 1996-07-08 SK SK62-98A patent/SK284202B6/sk not_active IP Right Cessation
- 1996-07-08 MX MX9709099A patent/MX9709099A/es active IP Right Grant
- 1996-07-08 IL IL12211896A patent/IL122118A/xx not_active IP Right Cessation
- 1996-07-08 DK DK96924368T patent/DK0848705T3/da active
- 1996-07-08 CZ CZ2004630A patent/CZ294740B6/cs not_active IP Right Cessation
- 1996-07-08 RO RO98-00061A patent/RO120070B1/ro unknown
- 1996-07-08 HU HU9900678A patent/HU223599B1/hu active IP Right Grant
- 1996-07-08 KR KR10-1998-0700346A patent/KR100389518B1/ko not_active IP Right Cessation
- 1996-07-08 SI SI9630700T patent/SI1148049T1/xx unknown
- 1996-07-08 PT PT96924368T patent/PT848705E/pt unknown
- 1996-07-08 EA EA199800130A patent/EA000474B1/ru not_active IP Right Cessation
- 1996-07-08 AT AT96924368T patent/ATE208375T1/de not_active IP Right Cessation
- 1996-07-08 GE GEAP19964147A patent/GEP20002029B/en unknown
- 1996-07-08 JP JP50671097A patent/JP3296564B2/ja not_active Expired - Fee Related
- 1996-07-08 PL PL324496A patent/PL193479B1/pl unknown
- 1996-07-08 CZ CZ2004631A patent/CZ294695B6/cs not_active IP Right Cessation
- 1996-07-08 IL IL128862A patent/IL128862A/en not_active IP Right Cessation
- 1996-07-08 DE DE69634054T patent/DE69634054T2/de not_active Expired - Lifetime
- 1996-07-08 NZ NZ312907A patent/NZ312907A/xx not_active IP Right Cessation
- 1996-07-08 EP EP96924368A patent/EP0848705B1/en not_active Revoked
- 1996-07-08 CN CN96195564A patent/CN1087288C/zh not_active Expired - Lifetime
- 1996-07-16 ZA ZA9606044A patent/ZA966044B/xx unknown
- 1996-07-16 HR HR960339A patent/HRP960339B1/xx not_active IP Right Cessation
- 1996-07-16 AR ARP960103598A patent/AR003458A1/es unknown
- 1996-07-16 AR ARP960103600A patent/AR003459A1/es not_active Application Discontinuation
- 1996-07-17 CO CO96037514A patent/CO4700443A1/es unknown
- 1996-07-17 UY UY24285A patent/UY24285A1/es not_active IP Right Cessation
- 1996-07-17 PE PE1996000539A patent/PE1898A1/es not_active IP Right Cessation
- 1996-08-07 UA UA98020824A patent/UA51661C2/uk unknown
- 1996-08-14 TW TW085109893A patent/TW486467B/zh not_active IP Right Cessation
-
1998
- 1998-01-14 BG BG102187A patent/BG63630B1/bg unknown
- 1998-01-16 NO NO980207A patent/NO309898B1/no not_active IP Right Cessation
- 1998-04-30 UY UY24985A patent/UY24985A1/es not_active IP Right Cessation
- 1998-12-15 HK HK98113380A patent/HK1018052A1/xx not_active IP Right Cessation
-
2002
- 2002-01-17 JP JP2002008746A patent/JP4790194B2/ja not_active Expired - Lifetime
-
2003
- 2003-03-06 CY CY0300022A patent/CY2358B1/xx unknown
-
2005
- 2005-07-25 AT AT0050505U patent/AT8453U1/de not_active IP Right Cessation
-
2006
- 2006-08-08 IL IL177377A patent/IL177377A0/en not_active IP Right Cessation
- 2006-08-08 IL IL177376A patent/IL177376A0/en not_active IP Right Cessation
-
2010
- 2010-02-09 IL IL203847A patent/IL203847A0/en not_active IP Right Cessation
-
2011
- 2011-06-13 JP JP2011130841A patent/JP2011195592A/ja active Pending
-
2013
- 2013-12-19 JP JP2013262007A patent/JP2014051533A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03606B1 (et) | Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) | |
DK0839132T5 (da) | Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) | |
IL158790A0 (en) | Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) | |
ATE207465T1 (de) | Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin) | |
PL370061A1 (en) | Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1) | |
IL173651A0 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid | |
DE69616358D1 (de) | Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) | |
NZ507836A (en) | Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
LD4A | Amendment in the specification | ||
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20091231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
HC1A | Change of owner name |